ZoBio is the established, market leading supplier of an array of biophysical techniques to support modern drug discovery efforts.

In its 7 years of existence, ZoBio has established and demonstrated the efficacy of its proprietary Target Immobilized NMR Screening technology for the discovery of high quality, diverse fragment ligands for a wide array of challenging targets including membrane bound proteins, such as GPCRs. More recently, we have added orthogonal validation technologies such as SPR and protein observed NMR. To further support Fragment- and Structure-based drug discovery, ZoBio has introduced highly innovative, NMR-based methods to rapidly elucidate the structure of target-small molecule complexes.

ZoBio has integrated these technologies into an efficient pipeline to support hit to clinical candidate programs on targets that no other CRO can address.